Purple Biotech Ltd
Change company Symbol lookup
Select an option...
PPBT Purple Biotech Ltd
PRE Prenetics Global Ltd
APTV Aptiv PLC
$NQUSB60101015LMCAD Nasdaq US Offshore Drilling and Othe
CUTR Cutera Inc
FRD Friedman Industries Inc
PRPRF Prairie Provident Resources Inc
BAC Bank of America Corp
USB-R US Bancorp
BHR Braemar Hotels & Resorts Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Israel
Company profile

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Premarket

Last Trade
Delayed
$2.04
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.04
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
2

10-day average volume:
69,830
2

BGSF, Inc. to Host Fiscal 2022 Second Quarter Earnings Conference Call and Webcast

8:00 am ET July 21, 2022 (BusinessWire) Print

BGSF, Inc. (NYSE: BGSF), a leading national provider of workforce solutions, today announced it will discuss its second quarter 2022 financial results during a conference call and webcast on Thursday, August 4, 2022 at 9:00 a.m. ET. The teleconference will be hosted by Beth Garvey, Chair, President and Chief Executive Officer; and Dan Hollenbach, Chief Financial Officer. The related press release will be issued after the market closes on Wednesday, August 3, 2022.

Interested participants may dial 844-200-6205 (U.S. callers) or 929-526-1599 (all other locations) and provide access code 464896. A replay of the call will be available until Thursday, August 11, 2022. To access the replay, please dial 929-458-6194 (U.S. Callers), 866-813-9403 (U.S. Toll Free callers), or +44 204-525-0658 (all other locations) and enter access code 400404. The live webcast and archived replay are accessible at the investor relations section of the Company's website at www.bgsf.com.

About BGSF

With its home office in Plano, Texas, BGSF provides workforce solutions to a variety of industries through its various divisions in IT, Cyber, Finance & Accounting, Creative, and Real Estate (apartment communities and commercial buildings). BGSF has integrated several regional and national brands achieving scalable growth. The Company was ranked by Staffing Industry Analysts as the 79th largest U.S. staffing company and the 48th largest IT staffing firm in 2021. The Company's disciplined acquisition philosophy, which builds value through both financial growth and the retention of unique and dedicated talent within BGSF's family of companies, has resulted in a seasoned management team with strong tenure and the ability to offer exceptional service to our field talent and client partners while building value for investors. For more information on the Company and its services, please visit its website at www.bgsf.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005094/en/

SOURCE: BGSF, Inc.

Steven Hooser or Sandy Martin
Three Part Advisors
ir@bgsf.com 214.872.2710
comtex tracking

COMTEX_410667968/1006/2022-07-21T08:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.